Randomized controlled trial demonstrates improved renal outcomes with triple therapy in Col4a3-deficient mice, suggesting synergistic protection against progressive chronic kidney disease.
Experiments in mice suggest that triple RAS/SGLT2/MR blockade may substantially improve renal outcomes in Alport syndrome and possibly other progressive CKDs because of synergistic effects on the glomerular and tubulointerstitial compartments.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: